[1]Bell DW, Ellenson LH. Molecular genetics of endometrial carcinoma[J]. Annu Rev Pathol-Mech, 2019, 14: 339-367. [2]Wipperman M, Montrose DC, Gotto AM, et al. Mam-malian target of rapamycin[J]. Am J Pathol, 2019, 189 492-501. [3]Yoo SM, Lee CJ, Kang HC, et al. Epimagnolin targeting on an active pocket of mammalian target of rapamycin suppressed cell transformation and colony growth of lung cancer cells[J]. Mol Carcinogen, 2019, 58: 1221-1233. [4]Wang S, Gu M, Jiang H, et al. BMP-2 upregulates the AKT/mTOR pathway in breast cancer with microcalcification and indicates a poor prognosis[J]. Clin Transl Oncol, 2020, 22: 1263-1271. [5]Martino MCD, Koetsveld PMV, Feelders RA, et al. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer[J]. Endocrine, 2019, 64: 673-684. [6]Minami H, Fujiwara Y, Muro K, et al. Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers[J]. Cancer Chemoth Pharm, 2019, 84: 337-343. [7]Gao YT, Yu XD, Zhang FX, et al. Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8[J]. J Hepatobiliary Pancreat Sci, 2019, 26: 219-226. [8]Romera AE, Guardiola TC, Vielba MB, et al. HE4 tumor marker as a predictive factor for lymphatic metastasis in endometrial cancer[J]. Int J Gynaecol Obstet, 2020, 149: 265-268. [9]Xu YC, Pan SY, Jiang WX, et al. Effects of propofol on the development of cancer in humans[J]. Cell Proliferat, 2020, 53: 1-11. [10]Yu XD, Gao YT, Zhang FX, et al. Propofol inhibits pancreatic cancer proliferation and metastasis by up-regulating miR-328 and down-regulating ADAM8[J]. Basic Clin Pharmacol Toxicol, 2019, 125: 271-278. [11]Gao M, Guo R, Lu XH, et al. Propofol suppresses hypoxia-induced esophageal cancer cell migration, invasion, and EMT through regulating lncRNA TMPO-AS1/miR-498 axis[J]. Thorac Cancer, 2020, 11: 2398-2405. [12]Hu C, Liu ZG, Iwasaki M, et al. Propofol inhibits cancer malignancy by disturbing glucose metabolism through hypoxia-inducible factor-1α and pigment epithelium-derived factor modulation[J]. Briti J Anaesth, 2019, 123: 499-500. [13]张梦迪, 王亚南, 李杰, 等. 雷帕霉素下调mTOR-GP73通路抑制结直肠癌进程[J]. 基础医学与临床, 2020, 40: 934-939. [14]贺振华, 沈富辉, 曾凡钢, 等. 核干细胞因子主导的信号通路影响肿瘤发生发展的研究进展[J]. 基础医学与临床, 2020, 40: 547-551. [15]Chen Y, Yuan X, Zhang WH, et al. Discovery of novel dual histone deacetylase and mammalian target of rapa-mycin target inhibitors as a promising strategy for cancer therapy[J]. J Med Chem, 2019, 62: 1577-1592. |